Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NAPOLEON-2)
Background: Nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard second- or later-line regimen after gemcitabine-based therapy for patients with unresectable or recurrent pancreatic cancer (urPC). However, limited prospective clinical data on the efficacy and safety of NFF...
Spremljeno u:
| Glavni autori: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier
2025-06-01
|
| Serija: | ESMO Gastrointestinal Oncology |
| Teme: | |
| Online pristup: | http://www.sciencedirect.com/science/article/pii/S2949819825000196 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
